Research Project
Grant-in-Aid for Scientific Research on Priority Areas
To evaluate the safety, immune responses and antitumor responses after the administration of α-Galactosylceramide (αGalCer; KRN7000)-pulsed APCs, a phase I-II study in patients with non-small cell lung cancer (NSCLC) was carried out. αGalCer-pulsed APCs (1x10 9/m2) were intravenously administered four times to 17 cases. The estimated median survival time (MST) of the 17 cases was 18.6 months. Ten patients who displayed increased IFN-g producing cells (≥2 fold) showed prolonged MST (31.9 months) as compared to poor-responder patients (n=7, 9.7 months). The administration of αGalCer-pulsed APCs was well tolerated and was accompanied by the successful induction of NKT cell-dependent immune responses. These results are encouraging and warrant further evaluation for survival benefit of this immunotherapy.
All 2010 2009 2008 2007 2006 2005 Other
All Journal Article (96 results) (of which Peer Reviewed: 76 results) Presentation (102 results) Book (3 results) Remarks (4 results)
N a t. R e v. I m m u n o l. 10
Pages: 193-200
J Allergy Clin. I m m u n o l. 125
J.Immunol. 184
Pages: 127-133
J Allergy Clin.Immunol 125
Nat.Rev.Immunol. 10
J. Immunol. 183
Pages: 8203-8215
Pages: 7817-7824
Pages: 5388-5396
C a n c e r S c i. 100
Pages: 1092-1098
10025146740
S e m i n. I m m u n o l. 21
Pages: 78-83
F r o n t i e r s i n B i o s c i e n c e S1
Pages: 108-116
I m m u n o t h e r a p y 1
Pages: 73-82
J. Immunol. 182
Pages: 2492-2501
Frontiers in Bioscience S1
Semin.Immunol. 21
Cancer Sci. 100
Pages: 11092-1098
J.Immunol. 183
Proceedings of the 2^<nd> European Congress of Immunology
Pages: 157-159
J. E x p. M e d. 205
Pages: 2727-2733
J. Biol. Chem. 283
Pages: 28216-28225
J. Allergy C l i n. Immunol. 122
J. Exp. M e d. 205
Pages: 1369-1379
I n t. I m m u n o l. 20
Pages: 849-860
C u r r. O p i n. I m m u n o l. 20
Pages: 265-271
J. Exp. Med. 205
Pages: 1109-1120
C a n c e r S c i. 99
Pages: 638-645
10024004283
M o l. Ther. 16
Pages: 261-268
C a n c e r I m m u n o l. Immunother. 57
Pages: 337-345
J. BioL Chem. 283
Immunology 125
Pages: 377-386
J. Allergy Cliri. Immunol. 122
Pages: 512-520
Mt. Immunol. 20
Curr. Opin. Immunol. 20 : 20
Int. Immunot 20
Pages: 869-879
J. EXD. Med. 205
Cancer Sci. 99
Mol. Ther. 16
Cancer Immunol. Immunother. 57
C r i t. Rev. Immunol. 27
Pages: 539-546
J. I m m u n o l. 178
Pages: 4926-4936
40016084081
M o l. I m m u n o l. 44
Pages: 2249-2256
Crit. Rev. lmmunol. 27
13th International congress of Immunology.
Pages: 475-479
Allergy 62
Pages: 1451-1455
J. Immunol. 179
Pages: 3699-3706
Int. Immunol. 19
Pages: 755-762
J. Immunol. 178
Allergology International 56
Pages: 1-6
Mol. Immunol. 44
J. E x p. M e d. 203
Pages: 2929-2937
J. Immunol. 177
Pages: 7656-7664
J. I m m u n o l. 177
Pages: 5801-5810
C l i n. C a n. R e s. 12
Pages: 6079-6086
I m m u n i t y 24
Pages: 611-622
J. Immunol. 176
Pages: 2546-2554
P r o c. N a t l. A c a d. S c i. U S A 103
Pages: 2286-2291
40015396097
Diabetes 55・1
Pages: 34-39
J. Immunol. 176・4
Immunity 24・5
Clin. Can. Res. 12・20
J. Immunol. 177・9
Microbes and Infection 8・12-13
Pages: 2679-2685
J. Immunol. 177・12
J. Exp. Med. 203・13
Proc.Natl.Acad.Sci.USA 103(7)
Diabetes 55(1)
J.Immunol. 17・4
P r o c. N a t l. A c a d. S c i. U S A 102
Pages: 9253-9257
C r i t. R e v. I m m. 25
Pages: 361-374
J. Immunol. 175
Pages: 3648-3655
J. B i o l. C h e m. 280
Pages: 29409-29419
I n t. J. C a n c e r 117
Pages: 265-273
Proteomics 5・15
Pages: 4001-4011
Neuroreport 16・16
Pages: 1763-1767
Proc.Natl.Acad.Sci.USA 102・26
Crit.Rev.Imun. 25・5
J.Immunol. 175・6
J.Biol.Chem. 280・33
Int.J.Cancer 117・2
Int.Immunol 17・6
Pages: 759-768
S e m i n. I m m u n o l. (in press)
Semin.Immunol. (in press)
J.Immunol. (in press)
Proc.Natl.Acad.Sci.USA (in press)
Cancer Sci. (in press)
J.Immunol (in press)
Immunotherapy (in press)
Frontiers in Bioscience (in press)
J. Exp. Med. (In press)
Cancer Sci. (In press)
http://www.m.chiba-u.ac.jp/class/meneki/homeb.htm
http://www.isrt-gcoe-chiba.jp/